Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Voyager Therapeutics Inc (NASDAQ:VYGR) by 2.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 183,201 shares of the company’s stock after acquiring an additional 3,930 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Voyager Therapeutics were worth $1,722,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. BB Biotech AG lifted its holdings in shares of Voyager Therapeutics by 11.5% during the third quarter. BB Biotech AG now owns 2,822,641 shares of the company’s stock worth $53,404,000 after purchasing an additional 290,000 shares during the period. BlackRock Inc. lifted its holdings in shares of Voyager Therapeutics by 1.0% during the third quarter. BlackRock Inc. now owns 1,863,766 shares of the company’s stock worth $35,262,000 after purchasing an additional 18,060 shares during the period. Vanguard Group Inc lifted its holdings in shares of Voyager Therapeutics by 10.5% during the third quarter. Vanguard Group Inc now owns 1,196,594 shares of the company’s stock worth $22,640,000 after purchasing an additional 113,442 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Voyager Therapeutics by 10.5% during the third quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock worth $22,640,000 after purchasing an additional 113,442 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Voyager Therapeutics by 18.6% during the third quarter. Wells Fargo & Company MN now owns 534,087 shares of the company’s stock worth $10,105,000 after purchasing an additional 83,607 shares during the period. Institutional investors own 85.37% of the company’s stock.

In other news, major shareholder Neurocrine Biosciences Inc bought 4,179,728 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was acquired at an average price of $11.96 per share, with a total value of $49,989,546.88. Following the completion of the purchase, the insider now directly owns 4,179,728 shares of the company’s stock, valued at $49,989,546.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 33.60% of the stock is owned by company insiders.

VYGR has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price target on the stock in a report on Saturday, January 19th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Voyager Therapeutics in a report on Tuesday, January 15th. Cowen reiterated a “buy” rating on shares of Voyager Therapeutics in a report on Wednesday, February 27th. Finally, ValuEngine upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $24.00.

Shares of NASDAQ VYGR opened at $19.66 on Friday. Voyager Therapeutics Inc has a twelve month low of $7.76 and a twelve month high of $24.24. The firm has a market cap of $641.25 million, a P/E ratio of -7.15 and a beta of 2.77.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, February 26th. The company reported ($0.70) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.70). Voyager Therapeutics had a negative net margin of 1,158.79% and a negative return on equity of 120.82%. On average, analysts expect that Voyager Therapeutics Inc will post -2.93 EPS for the current fiscal year.

WARNING: “Raymond James Financial Services Advisors Inc. Acquires 3,930 Shares of Voyager Therapeutics Inc (VYGR)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/raymond-james-financial-services-advisors-inc-acquires-3930-shares-of-voyager-therapeutics-inc-vygr/2897510.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Recommended Story: Trading Strategy Methods and Types

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.